Cibus (CBUS) Return on Capital Employed (2017 - 2026)
Cibus (CBUS) posted Return on Capital Employed of 32.43% for Q4 2025, down 10.79% sequentially from 29.27% in Q3 2025, and up 4377.0% YoY from 0.72% in Q4 2024.
Cibus (CBUS) Return on Capital Employed (2017 - 2026) Analysis & Trends
Cibus has reported Return on Capital Employed for 9 years, with the latest figure at 32.43% in Q4 2025.
- Quarterly Return on Capital Employed rose 4377.0% year-over-year to 32.43% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 32.43% (up 4377.0% YoY) and the FY2025 annual result came in at 31.39%, up 2907.0% from the prior year.
- Return on Capital Employed eased to 32.43% in Q4 2025 per CBUS's latest filing, from 29.27% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 6.78% in Q3 2023 and troughed at 121.04% in Q1 2023.
- A 5-year average of 73.65% and a median of 86.9% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 9575 bps in 2023, then sank 10939 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 87.55% in 2021, then fell by 12 bps to 97.69% in 2022, then soared by 50 bps to 49.13% in 2023, then plunged by 55 bps to 76.2% in 2024, then jumped by 57 bps to 32.43% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 32.43%, 29.27%, and 87.35% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | -23.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.37% |
| Dec 31, 2025 | -32.43% |
| Sep 30, 2025 | -29.27% |
| Jun 30, 2025 | -87.35% |
| Mar 31, 2025 | -87.55% |
| Dec 31, 2024 | -76.20% |
| Sep 30, 2024 | -116.17% |
| Jun 30, 2024 | -65.15% |
| Mar 31, 2024 | -64.38% |
| Dec 31, 2023 | -49.13% |
| Sep 30, 2023 | -6.78% |
| Jun 30, 2023 | -8.43% |
| Mar 31, 2023 | -121.04% |
| Dec 31, 2022 | -97.69% |
| Sep 30, 2022 | -102.53% |
| Jun 30, 2022 | -86.44% |
| Mar 31, 2022 | -91.05% |
| Dec 31, 2021 | -87.55% |
| Sep 30, 2021 | -92.72% |
| Jun 30, 2021 | -88.01% |